Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | CES2 | O00748 | 2/20 | 0.49 |
| ▸ | CES1 | P23141 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL157181 | 0.87 | CA1 (0.60) | SMN1; SMN2RAB9ACA1CA2CA12 | |
| SCHEMBL17770569 | 0.81 | LMNA (0.60) | SMN1; SMN2RAB9AHPGDL3MBTL1LMNA | |
| SCHEMBL4416667 | 0.80 | CES2 (0.62) | HPGDLMNACES2CES1POLB | |
| SCHEMBL8668642 | 0.79 | ALDH1A1 (0.68) | SMN1; SMN2RAB9AHPGDL3MBTL1LMNA | |
| SCHEMBL27485399 | 0.78 | HPGD (0.49) | SMN1; SMN2RAB9AHPGDL3MBTL1LMNA | |
| SCHEMBL15979722 | 0.77 | CTNNB1 (0.60) | SMN1; SMN2RAB9AHPGDL3MBTL1CES2 | |
| SCHEMBL3854662 | 0.76 | KMT2A (0.53) | SMN1; SMN2RAB9AHPGDL3MBTL1LMNA | |
| SCHEMBL6225170 | 0.76 | CA1 (0.46) | SMN1; SMN2RAB9AHPGDCA1CA2 | |
| SCHEMBL3862642 | 0.76 | KMT2A (0.53) | SMN1; SMN2RAB9AHPGDL3MBTL1LMNA | |
| SCHEMBL12541 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540405-B2 | Diaminophenothiazinium derivatives for labelling biomolecules, method and substrate for labelling oligonucleotides, and oligonucleotides obtained | UNIVERSITE CLAUDE BERNARD LYON I (FR) | 2017-01-10 | — | — | US | disclosed |
| US-20150011712-A1 | DIAMINOPHENOTHIAZINIUM DERIVATIVES FOR LABELLING BIOMOLECULES, METHOD AND SUBSTRATE FOR LABELLING OLIGONUCLEOTIDES, AND OLIGONUCLEOTIDES OBTAINED | UNIVERSITE CLAUDE BERNARD LYON I (FR) | 2015-01-08 | — | — | US | disclosed |
| CN-103298939-A | Double stranded oligonucleotide compounds comprising positional modifications | QUARK PHARMACEUTICALS INC | 2013-09-11 | — | — | CN | disclosed |
| US-7507859-B2 | Functional synthetic molecules and macromolecules for gene delivery | FIFTH BASE LLC (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1644479-A4 | FUNCTIONAL SYNTHETIC MOLECULES AND MACROMOLECULES FOR GENE DELIVERY | GRINSTAFF MARK W (US) | 2008-04-23 | — | — | EP | disclosed |
| US-20060241071-A1 | Functional synthetic molecules and macromolecules for gene delivery | FIFTH BASE LLC | 2006-10-26 | — | — | US | disclosed |
| EP-1644479-A2 | FUNCTIONAL SYNTHETIC MOLECULES AND MACROMOLECULES FOR GENE DELIVERY | Grinstaff, Mark, W. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005007810-A2 | FUNCTIONAL SYNTHETIC MOLECULES AND MACROMOLECULES FOR GENE DELIVERY | GRINSTAFF MARK W (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241071-A1 | Functional synthetic molecules and macromolecules for gene delivery | ANXA6, STING1, POLRMT | SMN1; SMN2 3525/4885RAB9A 4484/4885HPGD 3336/4885 |
| US-20150011712-A1 | DIAMINOPHENOTHIAZINIUM DERIVATIVES FOR LABELLING BIOMOLECULES, METHOD AND SUBSTRATE FOR LABELLING OLIGONUCLEOTIDES, AND OLIGONUCLEOTIDES OBTAINED | POLRMT, RNASEH1, PDXK | SMN1; SMN2 3479/4885RAB9A 4797/4885HPGD 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.